摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-di methyl-1H-benzimidazole-2-carbaldehyde | 890656-23-2

中文名称
——
中文别名
——
英文名称
4,5-di methyl-1H-benzimidazole-2-carbaldehyde
英文别名
4,5-Dimethyl-1H-benzo[d]imidazole-2-carbaldehyde;4,5-dimethyl-1H-benzimidazole-2-carbaldehyde
4,5-di methyl-1H-benzimidazole-2-carbaldehyde化学式
CAS
890656-23-2
化学式
C10H10N2O
mdl
——
分子量
174.202
InChiKey
KRUPFSGDOXDDHU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    45.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Anti-angiogenic compounds
    申请人:Bradshaw W. Curt
    公开号:US20060205670A1
    公开(公告)日:2006-09-14
    The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.
    本发明提供了包括与抗体的结合位点连接的AA靶向剂-连接剂共轭物的AA靶向化合物。提供了化合物的各种用途,包括治疗与异常血管生成相关的疾病的方法。
  • [EN] PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12<br/>[FR] PYRAZOLOPYRAZINES AGISSANT SUR DES CANCERS PAR INHIBITION DE CDK12
    申请人:BAYER AG
    公开号:WO2021176049A1
    公开(公告)日:2021-09-10
    The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
    本发明提供了一般式(I)中X、R1、R2和R3如所述和定义的化合物,制备所述化合物的方法,用于制备所述化合物的中间化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物,特别是治疗癌症等高增殖性疾病的药物组合物,作为唯一药剂或与其他活性成分结合使用。
  • [EN] METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT DE TROUBLES D'UTILISATION D'ALCOOL ET DE MALADIES ASSOCIÉES
    申请人:PHARMATROPHIX INC
    公开号:WO2018039641A1
    公开(公告)日:2018-03-01
    Methods and compounds for treating alcohol use disorder and associated diseases. Included is the administering to a subject in need there of an effective amount of a compound having a modulating effect on p75NTR.
    治疗酒精使用障碍和相关疾病的方法和化合物。包括向需要的受试者施用对p75NTR具有调节作用的化合物的有效量。
  • [EN] NOVEL COMPOUNDS<br/>[FR] PIPERAZINEDIONES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'OXYTOCINE
    申请人:GLAXO GROUP LTD
    公开号:WO2006000399A1
    公开(公告)日:2006-01-05
    Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2, 6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    化合物的公式(I),其中R1是2-茚基,R2是1-甲基丙基,R3是从2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基中选择的基团,R4代表甲基,R5代表氢或甲基或者,R4和R5与它们连接的氮原子一起代表吗啡啉基团及其药用可接受的衍生物,描述了它们的制备过程,含有它们的药物组合物以及它们在医学中的用途,特别是作为催产素拮抗剂的用途。
  • [EN] SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS<br/>[FR] DICETOPIPERAZINES SUBSTITUEES UTILISEES COMME ANTAGONISTES DES OXYTOCINES
    申请人:GLAXO GROUP LTD
    公开号:WO2006000400A1
    公开(公告)日:2006-01-05
    Compounds of formula (IA) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 1-methyl-indazol-5-yl, R4 represents methyl and R5 represents hydrogen or methyl, and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    描述了式(IA)的化合物,其中R1是2-吲哚基,R2是1-甲基丙基,R3是1-甲基吲唑-5-基,R4代表甲基,R5代表氢或甲基,以及它们的药学上可接受的衍生物,以及它们的制备方法、含有它们的药物组合物和在医学上的用途,特别是它们作为催产素拮抗剂的用途。
查看更多